Therefore, the beneficial effects of PPARγ agonist treatment in neurodegenerative diseases could be due to inhibition of Cdk5 kinase activity and a subsequent reduction in tau phosphorylation. This evidence concerns the gene CDK5 and neurodegenerative disease.